

# Oxidation of 2,3- and 2,5-Dihydro-1*H*-1-Benzazepines by Hydride Transfer to an Iminium Ion: Synthesis of 3*H*-1-Benzazepines

## B. Kharraz\*, P. Uriac\*\*, S. Sinbandhitb, L. Toupetc

\*Laboratoire de Chimie Pharmaceutique, Université de Rennes I, Avenue du Professeur Léon Bernard, F 35043 Rennes Cedex, France

<sup>b</sup>Centre Régional de Mesures Physiques de l'Ouest and 'Groupe de Physique Cristalline, Université de Rennes I, Avenue du Général Leclerc, F 35042, Rennes, France


Key Words: 1-Benzazepines; Oxidation; HydrideTranfer; Iminium Ion

**Abstract** Some 3//-1-benzazepines were prepared by dehydrogenation of secondary 2.3- and 2.5-dihydro-1//-1-benzazepines involving a hydride <sup>3</sup>transfer to an iminium ion generated from a heterocyclic enamine and BF<sub>x</sub>. With 2.5-dihydro-1//-1-benzazepines the initial formation of 5//-1-benzazepines was observed, whose treatment in the presence of BF<sub>x</sub> led to 3//-1-benzazepines. The same rearrangement could be performed with t-BuOK. The hydride transfer was demonstrated using a deuterium labelled substrate. Tertiary dihydro-1-benzazepines were also oxidized but underwent rearrangement to naphthylamine derivatives.

## INTRODUCTION

In a previous article<sup>1</sup>, we reported the synthesis of 5H-1-benzazepines 4 by electrochemical oxidation of 2,5-dihydro-1H-1-benzazepines 1. In this paper we describe the preparation of 3H-1-benzazepines 5, isomers of 4, by two synthetic pathways. The first is the chemical oxidation of the 2,5- and 2,3-dihydro-1H-1-benzazepines 1 and 2, the second the rearrangement of 5H-1-benzazepines 4.

The use of classical oxidation reagents<sup>2</sup> such as MnO<sub>2</sub> or DDQ has not been successful. Therefore we employed the strategy previously described by Cook<sup>3</sup>, involving a hydride transfer from secondary amines (in our case dihydro-1*H*-1-benzazepines 1 and 2) to an iminium ion, acting as an hydride acceptor. The rearrangement of 5*H*-1-benzazepines 4 into 3*H*-1-benzazepines 5 was achieved either by a Lewis acid (BF<sub>3</sub>) or a strong base (t-BuOK).




Scheme 1

## RESULTS

## Oxidations |

The benzazepines 1<sup>4</sup> or 2<sup>5</sup> were allowed to react in refluxing toluene with the enamine 3f<sup>6</sup> in the presence of BF<sub>3</sub>-Et<sub>2</sub>O (scheme 2). In every case 3f led by reduction to 6f, whose the thermodynamically favoured 3R\*5R\* diastereomer was obtained as the major product (90%). Depending on the starting material, three oxidation behaviours were observed



The high stability of  $3\mathbf{f}$ , prepared by transposition of the 1.3,5-trimethyl-2,3-dihydro-1*H*-1-benzazepine  $2\mathbf{f}$  in refluxing 2M aqueous HCl, seems to be fundamental. Indeed, substitution of  $3\mathbf{f}$  by another enamines such as  $\mathbf{V}^7$  or  $\mathbf{VI}^8$  (fig 1) remained unsuccessful.

## 2,3-dihydro-1H-1-benzazepines 2a-e (scheme3)

The oxidized 3H-1-benzazepines 5a-c were obtained after separation from polymers by column chromatography. For the products 5a-c the best yields (30-35%) were observed for a reaction time of 4-5h. However yield was reduced to 10% in the case of 5d (R'=H). With the benzazepine 2e, bearing two hydrogen atoms at C-2, oxidation only led to polymers.

Yields

R

CH<sub>3</sub>

R

CH<sub>3</sub>

R

CH<sub>3</sub>

R

R


$$R^2 = (H_3, R^5 = (H_3, Z = H) : 5a = 30 \cdot 35 \% R^2 = (H_3, R^5 = (H_3, Z = (H_3, R^5 = (H_3, Z = (H_3(R)) : 5b) " R^2 = (H_3, R^5 = (H_3, Z = (H_3(R)) : 5c) " R^2 = (H_3, R^5 = H, Z = H) : 5d = 10 \% R^2 = H, R^5 = H, Z = H : 5e = 0 \% (polymers)$$

Scheme 3

## 2.5-dihydro-1H-1-benzazepines 1a-e (scheme 4, fig 2)

The oxidation of derivatives 1a-d led first to the benzazepines 4a-d, whose BF<sub>3</sub> catalysed isomerisation gave benzazepines 5a-d. With 1a and 1b, the intermediates 4a and 4b were difficult to isolate because of their rapid rearrangement into the final products 5a and 5b. Compound 1c led to the

accumulation of 4c because the transformation of 4c into 5c was slow. In the case of 1d ( $R^5 = H$ ), as well as 2d the yields were low (15%). The reaction had to be stopped after two hours to obtain a 20:80 mixture of 4d + 5d. Compound 1e ( $R^2 = H$ ) resulted exclusively in polymer formation.



## N-methyl derivatives 1f and 2f (scheme 5)

Oxidation of the N-methyl benzazepines resulted in the formation of the naphthyl-1-amine derivatives 7 and 8. The expected 1H-1-benzazepines X were not detected. The presence of  $CH_3$  at C-2 induced the formation of polymers. The formation of small amounts of 8 could be explained by a  $BF_3$  catalysed transformation of 7. Indeed, in our experimental conditions 7 gave a 30:1 mixture of 8 and 9 (scheme 6).

#### Rearrangements


The electochemically prepared 5H-1-benzazepines 4 underwent rearrangement into 3H-1-benzazepines 5 by either a strong base in an aprotic medium (t-BuOK, DME) or a Lewis acid (BF<sub>3</sub>) in toluene. With t-BuOK benzazepines 5 were obtained in 80% yield. This method was employed to prepare pure samples of 5d, 5d' (Et-2 analog of 5d) and 5c for the structural study. In contrast BF<sub>3</sub> induced significant formation of polymers.

## STRUCTURAL ELUCIDATIONS

Detailled spectroscopic data are reported in the Experimental Section but the major observations are described in the following.

<u>3*H-1-benzazepines*</u> 5: The m/z value of the molecular ion confirmed the dehydrogenation of 1 or 2. The formation of the azomethine was attested by the presence of the C =N streching vibrations at 1640 cm<sup>-1</sup> and by the  $\delta$ C-2 at 164-168 ppm. The complete attribution of the NMR signals was achieved using 2D NMR ( $^{13}$ C- $^{1}$ H correlation) in addition to selective decoupling and NOE experiments The X-ray crystallographic study of 5a established unambigously the structure shown in *fig* 3.

Naphthylamines 7,8,9°: Hydrogen signals were attributed by selective decoupling and NOE experiments (fig 4). Carbons were assigned on the basis of <sup>13</sup>C-<sup>1</sup>H correlations.



## 2,3,4,5-tetrahydro-1H-1-benzazepines 6

Reduction of 3 was confirmed by MS. The relative configuration of the diasteromers was established by comparison of their  $^{1}$ H NMR data with those of the previously described compound  $IX^{6}$ . In  $^{13}$ C NMR, the shifting of the CH-3 signal of the  $^{3}$ R\*5S\* isomer confirmed the *cis* relationship between H-3 and CH<sub>3</sub>-5 (*fig* 5).

## **DISCUSSION**

In agreement with the study of Cook<sup>3</sup> the following mechanism (scheme 7) can explain the oxidation of 1 and 2

scheme 7

The iminium ion 3'f, acting as an hydride acceptor in our experiments, is formed by the  $\beta$ -attack of BF<sub>3</sub> on the heterocyclic enamine 3<sup>10</sup>. The abstraction of a hydride ion from the  $\alpha$ -carbon of benzazepines 1 or 2 and its nucleophilic attack on the  $\alpha$ -carbon of the iminium 3'f resulted in the formation of the reduced benzazepine 6f and of the carbonium ion 1. This hydrid transfer from our heterocyclic amines to 3'f has been demonstrated using the deuterium labelled compound 1a as starting material, which was obtained as a 20/80 mixture of the 2R\*5R\* and 2R\*5S\* isomers, by LiAlD<sub>4</sub> reduction of 4a The deuterium incorporation at C-2 of the major isomer of 6f ( $\approx 60\%$ ) was controlled by <sup>1</sup>H and <sup>2</sup>H NMR. (scheme 8).

scheme 8

As shown on scheme 9, the transformation of the carbonium I depended on the nature of the amino group.

-If the starting benzazepines were secondary  $(R^1 = H)$ , deprotonation occurred at N-1 and the 3H-1-benzazepines 5 were formed either directly (a) or after rearrangement (b).

-If 1 or 2 were tertiary ( $R^1 = CH_3$ ), the elimination of the proton from C-3 (c) or C-5 (d) is presumed to result in formation of the 1H-1-benzazepine X; however this was not isolated. As reported in the literature<sup>11</sup>, this antiaromatic heterocycle X underwent the aromatic naphthyl-1-amine derivative T by electrocyclisation into the aziridino derivative III. This aromatisation was impossible if  $R^2 \neq H$  and then polymers were obtained.

The base catalysed rearrangement of benzazepines 5 into 4 involved an allylic carbanion II. In a previous paper<sup>5</sup>, concerning the preparation of 2,3-dihydro-1*H*-1-benzazepines from 2,5-dihydro-1*H*-1-benzazepines, such an intermediate was postulated.

Z

$$R^{5}$$
 $R^{5}$ 
 $R^{5}$ 

## CONCLUSION

Use of hydride acceptors such as iminium ions is an interesting alternative for the preparation of imines from secondary amines. Application of this strategy to 2,5 or 2,3-dihydro-1H-benzazepines led to the synthesis of the rarely described 3H-1-benzazepines $^{12}$  which may also be obtained by base catalysed rearangements of 5H-1-benzazepines. However, in order to develop this synthetic methodology, the use of others iminium ions or carbonium ions $^{13}$ , more easily available, is under investigation.

## **EXPERIMENTAL SECTION**


#### General

Melting points were determined on a Kofler apparatus and were not corrected. Elemental analyses were carried out at the Faculté de Pharmacie (Université de Paris XI). Purification by column chromatography were done on 70-230 mesh silica gel (Merck). GC were done on a glass capillary column(SE 52) with a Carlo Erba Fractovap 4160 instrument. TLC analyses were performed on pre-coated aluminium sheets of silica gel 60 F<sub>254</sub> (layer thickness: 0.22 mm)(Merck). Indicated R, values were determined using as eluent (50:50 petroleum ether-ether). IR spectra were recorded on a Perkin-Elmer 16 PC. NMR spectra were recorded on a Brucker AM 300 FT spectrometer at the Centre Régional de Mesures Physiques de l'Ouest (CRMPO) at 300 MHz (<sup>1</sup>H) or 75 Mhz (<sup>13</sup>C). Chemical shifts were expressed in ppm downfield from TMS and coupling constants (J) in Hertz. The solvant was CDCl<sub>3</sub>. H NMR : AB systems were presented in the following order: H- $\alpha$  ( $\delta$  : centered) the more deshielded, H- $\beta$  ( $\delta$  centered) the more shielded, JH- $\alpha$  H- $\beta$ . Long-range coupling constants were indicated using Jlr. <sup>13</sup>C NMR broad band and gated decoupling spectra were recorded. The assignments were made using chemical shifts and coupling constants (1 J and long-range coupling). Values with an asterisk \* could be interverted. 2D NMR: the sequences were indicated in the text. The high resolution mass spectra were determined on a Varian MAT 311 double-focusing instrument at the CRMPO with a source temperature of 140°C, an ion accelerating potential of 3 kV, and ionizing electrons of 70 eV and 300 mA. A direct Insertion Probe was used. Starting material

The starting benzazepines were prepared according to references<sup>4,5,6</sup>. The deuterium labelled compound 1a was prepared from the imine  $4a^1$  by  $D_4LiAl$  reduction in the THF (yield 50%). Synthesis procedures

- Method A :Oxidations: The BF<sub>3</sub>-Et<sub>2</sub>O (0,2 ml) was added to a refluxing solution of the starting benzazepines 1 or 2 (5 mmol ) and of the enamine 3f (5 mmol ) in 15 ml of toluene . The reaction end was determined by GC or TLC (6-8h). The organic layer was separated after treatment with an alkaline solution and the aqueous phase was extracted with ether. The combined organic layers were dried ( $K_2CO_3$ ) and

concentrated. The residue was purified by column chromatography and, depending of the eluent 3f, 6f R\*S\*, 6f R\*R\* and 5 or 7, 8, 9 could be separated and purified:



The purity (= 98%) was checked by GC, TLC and MS. The 3*H*-1-benzazepines 5 have to be stored at -5°C, at RT or in CDCl, degradation occured in the course of days. Compounds 5 showed a characteristic smell.

For the study of the reaction evolution by GC the tetrahydronaphthalene was used as internal standard.

- Method B: Rearrangement: The DME solution of the 5H-1-benzazepines (1mmol/2ml) 4d, 4d'and 4c were stirred 1h at RT in the presence of an excess of t-BuOK. After usual treatement—the 3H-1-benzazepines were purified by column chromatography.

## 2,3,5-trimethyl-3H-1-benzazepine: 5a

```
<u>m.p</u>: 50-51. <u>LR v(cm^{-1}):C=N (1632)</u>
```

 $^{1}$ H NMR: CH<sub>3</sub>-2(s:2.24); CH<sub>3</sub>-3(d:1.39), H-3(m.1.86); H-4(dd:5.36), JH-4 H-3 (5.8), Jld(1);

 $CH_3$ -5(sm: 2.16); H-6(d: 7.55); H-7(t: 7.13); H-8(t: 7.32); H-9(d: 7.30);

NOE: Irradiation of CH<sub>3</sub>-5: H-4 (+ 12%); H-6 (+ 20%) and of CH<sub>3</sub>-3: H-4 (+ 14%)

<sup>13</sup>C NMR CH<sub>3</sub>-2(22.68), C-2(166.82), CH<sub>3</sub>-3(15.62), C-3(38.04), C-4 (127.70), CH<sub>3</sub>-5(20.87), <sup>3</sup>J(6),

C-5(133.36); C-5a(131.26); C-6(126,45); C-7(123.11); C-8(126.67); C-9(126.34); C-9a(146.18).

2D NMR: 13C 1H correlation

M.S. m/e, rel.intensity % M. 185, 79; 184, 29; 170, 100; 129, 27; 128, 38; 127, 15; 115, 15; 77, 15

Exact mass: m/e = 185.1208 (calc. for  $C_{13}H_{15}N$  m/e = 185.12044)

## 2,3,5,8-tetramethyl-3H-1-benzazepine: 5b

 $I.R v(cm^{-1}):C=N:(1644)$ 

<sup>1</sup>H NMR: CH<sub>3</sub>-2(s:2.23), CH<sub>3</sub>-3(d:1.39); H-3(m:1.87); JH-3 H-4 (5.7); H-4(dd: 5.30), Jld(1.2);

CH<sub>3</sub>-5(sm:2.14); H-6(d:7.44); H-7(dd:6.97); CH<sub>3</sub>-8(s:2,38); H-9(sm:7.15).

NOE: irradiation of CH<sub>3</sub>-5: H-4 (+9%), H-6 (+14%)

 $\frac{13}{\text{C}}$  NMR: CH<sub>3</sub>-2(22.66); C-2(166.52); CH<sub>3</sub>-3(15.65); C-3(38.11); C-4(126.70) ,CH<sub>3</sub>-5(20.88)<sup>3</sup>J(6) ; C-5(133.31) ; C-5a(128.66) ; C-6(126.21) ; C-7(124.42) ,CH<sub>3</sub>-8(21.13) ; C-8(136.48) ; C-9(126.59) ;

C-9a(146.35). 2D NMR: 13C 1H correlation

M.S. m/e, rel. intensity %: M: 199, 88, 198, 18, 184, 100, 143, 9, 128, 21, 115, 9

Exact mass: m/e = 199.1376 (calc. for  $C_{11}H_{12}N$  m/e = 199.13609)

## 2,3,5,9-tetramethyl-3H-1-benzazepine: 5c

Method A: after 7h obtention of a mixture of 5c (65%) and 4c (35%). Method B: obtention of 5c pure I.R v(cm<sup>-1</sup>):C=N (1634)

<sup>1</sup>H NMR: CH<sub>3</sub>-2(s:2.23); CH<sub>3</sub>-3(d:1.41); H-3(m:1.77); H-4(dd:3.9), JH-3 H-4(5.6), Jld(1); CH<sub>3</sub>-5(sm:2.15); H-6(d:7.42); H-7(dd:7.04); H-8(dm:7.16); CH<sub>3</sub>-9(s:2.39).

<sup>13</sup>C NMR: CH<sub>3</sub>-2(22.36); C-2(164.40); CH<sub>3</sub>-3(15.64); C-3(38.43); C-4(127.80); \*C-5(133.56); C-5a(130.48) CH<sub>3</sub>-5(21.14) J (6); C-6(123.93); C-7(122.63); C-8(127.74); CH<sub>3</sub>-9(19.03) J(5); \*C-9(133.60); C-9a(145.13).

M. S. m/e, rel.intensity %: M5 199,100; 198,14; 184, 83; 171, 19; 170, 13; 169, 8; 143, 13; 141, 9; 128, 22; 115, 19. Exact mass: m/e = 199.1362 (calc. for C<sub>1</sub>,H<sub>1</sub>,N m/e = 199.13609)

## 2,3-dimethyl-3H-1-benzazepine: 5d

IR:  $v(cm^{-1})$ : C=N: (1634)

<sup>1</sup>H NMR: CH<sub>3</sub>-2(sm:2.25); CH<sub>3</sub>-3(d:1.45); H-3(m:1.92); H-4(dd:5.54); JH-4 H-5(9.5); JH-4 H-3(5.5);

H-5(dd:6.68); JH-5 H-3(1.6); H-6(d:7.31); H-7(t:7.13); H-8(t:7.26); H-9(d:7.42)

<sup>13</sup>C NMR: CH<sub>3</sub>-2(23.14); C-2(164.37); CH<sub>3</sub>-3(15.53); C-3(38.78); C-4(130.00); C-5(128.45); C-5a(128.81); C-6(129.35); C-7(123.25); \*C-8(126.82); \*C-9(126.87); C-9a(146.69).

```
M.S. m/e, rel.intensity %: M: 171,100; 170, 29; 156, 59; 144,14; 143, 17); 130, 17; 129, 35; 128, 22;
127.17:115.44 Exact mass: m/e = 171.1041(calc. for C, H, N m/e = 171.10479)
2-ethyl-3-methyl-3H-1-benzazepine: 5d'
IR: v(cm^{-1}) C=N: (1664)
<sup>1</sup>H NMR: CH,-CH,-2(m 2.60 and t:1.17); H-3(m:2.08); CH,-3(d:1.39); H-4(dd:5.57), JH-4 H-3(6), JH4-
H-5(9.4); H-5(dd:6.67), JH-5 H-3(1.1); H-6(d:7.34); H-7(t:7.13); H-8(t:7.30); H-9(d:7.41)
<sup>13</sup>C NMR: CH.-CH.-2(12.04-29.42), C-2(168.84), CH.-3(14.69), C-3(38.88), C-4(130.18), C-5(128.16),
C-5a(128 69), C-6(129 32), C-7(123 17), C-8(126 73), C-9(12 02), C-9a(146 72). For attribution of C-7 and
C-9 irradiation at 7.13 ppm and for C-5 and C-6 at 6.678 ppm. 2D NMR. <sup>13</sup>C <sup>1</sup>H correlation
M.S. m/e, rel intensity % M- 199,88; 198,18; 184,100; 143, 9; 128, 21; 115, 9.
Exact mass: m/e = 199.1376 (calc. for C_{11}H_{17}N m/e = 199.13609)
N-methyl-2,4-dimethylnaphtyl-1-amine: 7
m.p: 37-39. LR v(cm^{-1}):N-H (3372)
<sup>1</sup>H NMR: NH(s:3.28); CH<sub>3</sub>N-1(s:2.88); CH<sub>3</sub>-2(s:2.41); H-3(s:7.13); CH<sub>3</sub>-4 (s:2.60), H-5(d:7.92);
H-6(t:7.43); H-7(t:7.47); H-8(d:8.12).
NOE: irradiation of CH<sub>3</sub>-4:H-5 (+20%) and of CH<sub>3</sub>-2: H-3 (+15%)
<sup>13</sup>C NMR; CH<sub>3</sub>N-1(37.09); C-1(142.17); CH<sub>3</sub>-2(17.71); *C-2(128.93); C-3(130.12); CH<sub>3</sub>-4(18.93);
C-4(132.44); *C-4a(128.84); C-5(124.62), C-6(124.70); C-7(125.15); C-8(123.24); C-8a(125.42).
2D NMR: 13C 1H correlation
M.S. m/e, rel.intensity %: M= 185,100; 184, 15; 170, 72; 169, 9; 168, 13; 154, 8; 143,13; 141, 8; 128, 19
; 115,9 . Exact mass : m/e = 185.1208 (calc. for C_{12}H_{15}N m/e = 185.12044)
2,4-dimethylnaphtyl-1-amine: 8
m.p : 60-61. I.R v(cm^{-1}):N-H (3365)
<sup>1</sup>H NMR: NH(s:3.85), CH<sub>3</sub>-2(s:2.31); H-3(s:7.06); CH<sub>3</sub>-4(s:2.57); H-5 H-8 (m:7.78-7.94); H-6 and
H-7(m:7.42-7.47).
N,N-dimethyl-2,4-dimethylnaphtyl-1-amine: 9
IR: absence of vNH
<sup>1</sup>H NMR: 2N-CH<sub>3</sub>-1(s:2.87); CH<sub>3</sub>-2(s:2.31); H-3(s:6.98), CH<sub>3</sub>-4(s:2.49); H-5 and H-8(m:7.70-8.20); H-6
and H-7 (m: 7.25-7.40).
M.S. m/e, rel.intensity %: M: 17, 84; 174, 16; 160, 25; 146, 8; 144, 9; 13, 30; 132, 100; 118, 18; 117,
21; 91, 14. Exact mass: m/e = 175.1358 (calc. for C_1 H_{17} N m/e = 175.13609)
(3R*5R*) 1,3,5-trimethyl-2,3,4,5-tetrahydro-1H-1-benzazepine : 6f
<sup>1</sup>H NMR: CH<sub>1</sub>-1(s:2.84); H-2(dd:2.83), JH-2 H-2(11.6), JH-2 H-3(1.5); H-2(dd:2.71), JH-2 H-3(3.2);
CH<sub>3</sub>-3(d:0.85); H-3(m:.68); 2H-4(m:1.45); H-5(m:3.24); CH<sub>3</sub>-5(d:1.30); Ar(m:6.85-7.18).
<sup>13</sup>CNMR: CH<sub>3</sub>-1(42.02); C-2(62.85); CH<sub>3</sub>-3(19.72); C-3(30.24); C-4(41.58); CH<sub>3</sub>-5(19.11); C-5(34.41);
C-5a(138.25); C-6(126.04); C-7(120.83); C-8(126.40); C-9(116.32); C-9a(150.46).
For attribution of CH<sub>3</sub>-3 irradiation at 0.98 and for C-5 at 3.37.
M.S. m/e, rel intensity %: M: 189, 100; 188, 7; 174, 37; 160, 19; 14, 17); 146, 18; 144, 9; 132, 60; 117,
13; 91, 8. Exact mass: m/e = 189.1509 (calc. for C_{12}H_{10}N m/e = 189.15174)
Analysis: Calc.%
                      C: 82,48; H: 10,12; N: 7,40
           Found %
                        C: 82,31; H: 10,23; N: 7,31
(3R*5S*) 1,3,5-trimethyl -2,3,4,5-tetrahydro-1H-1-benzazepine : 6f
<sup>1</sup>H NMR: CH<sub>3</sub>-1(s:2.89); H-2a (ddd:2.92), JH-2a H-3(3.8), JH-2a H-2b(12.7), JH-2a H-4(1.5);
H-2b(dd:2.18), JH-2b H-3(11.1); H-3(m:2.01); CH,-3(d:0.79); H-4(dm:1.74), JH4 H-3(4), JH-4 H-5(1.6),
JH-4 H-4(13.26), H-4(dm:0.89), JH-4 H-3(11.4), JH-4 H-5(10.5), H-5(m:3.01), CH,-5(d:1.35);
Ar(m:6.97-7.23).
<sup>13</sup>C NMR: CH,-1(43.59); C-2(64.06); *C-3(35.16); CH,-3(19.73); C-4(42.86); CH,-5(21.54); *C-5(34.40);
```

## C-5a(140.24); C-6(125.44); C-7(121.92); C-8(126.19); C-9(116.34); C-9a(152.82). (2R\*3S\*5S\*) 1,3,5-trimethyl -2,3,4,5-tetrahydro-1*H*-1-benzazepine D labelled at C-2: 6f

<sup>1</sup>H NMR: intensity of H-2a(2.83): 100%, intensity of H-2b(2.71): 35%

<sup>2</sup>H NMR: (CCl<sub>4</sub>): CDCl<sub>3</sub> at 7,274 ppm; D-2 at 2.78ppm.

**X-ray data of 5a:**  $C_{13}H_{15}N$ : Mr = 185.27, monoclinic,  $P_{21}/n$ , a = 12.793(4), b = 9.474(4), c = 8.631(3) Å,  $\beta = 92.11(2)^{\circ}$ , V = 1045.4(5) Å  $^{-3}$ , Z = 4,  $D_X = 1.18$  Mg m  $^{-3}$ ,  $\lambda(\text{MoK}\alpha) = 0.70926$ Å,  $\mu = 0.64$  cm  $^{-1}$ , F(000) = 400, T = 120 K, final R = 0.049 for 1067 observations. The sample (0.25\*0.30\*0.45 mm) is studied on an automatic diffractometer CAD4 ENRAF-NONIUS with graphite monochromatized MoK $\alpha$  radiation. Due to a low melting point, the study was made at low temperature (120 K). The cell parameters are obtained by fitting a set of 25 high-theta reflections. The data collection  $(2\theta_{max} = 50^{\circ}$ , scan  $\omega/2\theta = 1$ ,  $t_{max} = 60$ s, range HKL: H 0.9 K 0.10 L -14.14, intensity controls without appreciable decay (0.3%) gives 1706 reflections from which 1067 were independent  $(R_{int} = 0.020)$  with I>3 $\sigma(I)$  Atomic scattering factors from International Tables for X-ray Crystallography All the calculations were performed on a Digital MicroVAX 3100 computer with the MOLEN package 15

## References

- Kharraz, B, Uriac, P, Toupet, L, Hurvois, J P; Moinet, C., Tallec, A Tetrahedron., 1995, 51, 9611-9624.
- 2a Cromarty, A., Proctor, G. R. and Shabbir, M. J. Chem. Soc., Perkin I, 1972, 2012-2017.
- 2b Peaston, W. C. and Proctor, G.R. J. Chem. Soc. (C), 1968, 2481-2484.
- 2c Lennon, M., McLean, A, McWatt, I. and Proctor, G. R., J. ('hem. Soc. Perkin I, 1974, 1828-1833)
- 2d Hudlicky, M.; "Oxidations in Organic Chemistry", ACS Monograph 186, 1990, 234-248.
- 3 Cook, A. G and. Schulz, C. R, J. Org. Chem., 1967, 32, 473-475.
- 4a Tiollais, R.; Lattes, A.; Bouget, H.; Huet, J & Bonnic, J C.R. Acad. Sc., 1968, 267, série C, 1350-1351.
- 4b Bonnic, J.; Huet, J.; Lattes, A. & Bouget, H., C.R. Acad. Sc., 1971, 272, série C, 672-674, Ibid, 1974, 278, série C, 1461-1463.
- 4c Bonnic, J., Uriac, P., Bouget, H & Huet, J., C. R. Acad. Sc., 1978, 286, série C. 83-84
- 5a Uriac, P., Bonnic, J & Huet, J. J. Chem. Res., 1984, (S), 142-143, (M), 1461-1465.
- 5b Uriac, P. & Huet J. Org. Magn. Reson., 1983, 21, 487-490.
- 6 Uriac, P., Corbel, J.C., Bouget, H & Huet, J. Bull. Soc. Chim. Fr., 1987, 1045-1050
- 7 Benzing, E., Angew. ('hem., 1959, 71, 521.
- 8 Blomquist, A.T. & Moriconi, E.J., J. Org. Chem., 1961, 26, 3761-3769
- 9a Seita, J., Drakenberg, T & Sandstrom, J. Org. Magn. Resonance, 1978, 11, 239-245
- 9b Wilson, N.K.; Stothers, J.B. Org. Magn. Resonance, 1974, 15, 31-39.
- 10a Cook, A. G., "Enamines", 2nd edition, Dekker, New York, 1988, 181-246.
- 10b Sansoulet, J & Welvart, Z. Bull. Soc. ('him. Fr., 1962, 77-80.
- 11a Ikeda, M.; Onno, K.; Uno, T & Tamura, Y. Tetrahedron Lett., 1980, 3403-3406.
- 11b Ikeda, M., Onno, K., Takahashi, M., Uno, T & Tamura, Y. J. Chem. Soc. Perkin I, 1982, 741-748.
- 11c Notyka L.A., Tetrahedron Lett., 1985, 26, 2827-2830.
- 12a Plieninger, H & Wild D. Chem. Ber., 1966, 99, 3070-3075.
- 12b Ishigura, Y., Funakoshi, K., Saeki, S & Humana, M., Heterocyles, 1983, 20, 1545-1547.
- 12c Proctor, G.R., Azepine Rings System containing two rings, (Rosowsky, A.Edit.), Wiley, New York, 1984, 1, 637-775.
- 13a Bauld, N.L. & Rim, Y.S., J. Am. Chem. Soc., 1967, 89, 6763 -6764
- 13b Volz, H. & Kiltz, H.H., Liebigs Ann. Chem., 1971, 752, 86-101.
- 14 International Tables for X-ray Crystallography, 1974. Vol. IV. (Birmingham: Kynoch Press).
  (Present distributeur D.Reidel, Dordrecht.)
- Delft, 1990; Enraf-Nonius Molecular Structure Determination Package, Molen Version 1990. Enraf-Nonius, Delft, The Netherlands.

Acknowledgments: The authors thank Mrs Le Roch, Mr Bourges, Cupif and Ternisien for technical assistance and Mr Guenot of the CRMPO (MS).